• AnorMed Inc., of Vancouver, British Columbia, finished enrolling 300 multiple myeloma patients in the first of two pivotal Phase III trials of Mozobil for stem cell transplant. Recruitment continues for the second Phase III study in non-Hodgkin's lymphoma, and 300 patients are expected to be enrolled in that trial by the end of the year. Both trials are designed to evaluate Mozobil in a standard stem cell mobilization regimen. AnorMed anticipates reporting top-line data by the second quarter of 2007.

• BioAxone Therapeutic Inc., of Montreal, completed its targeted patient enrollment of the Phase I/IIa North American trial of Cethrin in acute spinal cord injury. Cethrin, a recombinant protein-based inhibitor of Rho signaling, is co-delivered with a fibrin sealant and administered once directly onto the surface of the spinal cord during spinal decompression surgery. Results of the open-label safety and pharmacokinetic trial conducted with 37 patients in the U.S. and Canada are expected this fall.

• Oncolytics Biotech Inc., of Calgary, Alberta, began patient enrollment in its Phase Ib UK trial investigating Reolysin in combination with radiation therapy in advanced cancers. The trial will treat patients with a range of two to six intratumoral doses of Reolysin. Patient enrollment in the Phase Ia combination Reolysin/radiation trial was completed in June, and preliminary analysis demonstrated evidence of both local and systemic response. The primary objective of the Phase Ib trial is to determine the maximum tolerated dose, dose-limiting toxicity and safety profile of Reolysin when administered intratumorally to patients receiving radiation.

• PowderMed Ltd., of Oxford, UK, submitted regulatory documentation to the UK Medicines and Healthcare Products Regulatory Agency for permission to conduct a clinical trial to test its H5N1 or avian influenza vaccine. The trial will be conducted at a clinical research unit in London. The new vaccine is based on PowderMed's needle-free injection device that fires gold particles coated with DNA at high speed into the immune cells of the skin.